CPRX · Catalyst Pharmaceuticals, Inc.

Track CPRX — free

Market Cap

$3.85B

122.38M

No Price Data

No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 11, 2026

Equibles Rating

blended score · not investment advice

Overall

Strong Buy

SellHoldBuy

Technical Limited Momentum Limited Sentiment Bullish Fundamentals Excellent Quant / Vol Limited

Market backdrop VIX 16 · calm Equity put/call 0.58

Technical

price trend

Limited

Not enough data for a confident read.

Momentum

relative strength

Limited

Not enough data for a confident read.

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50/200-day averages unavailable

Institutional flow Accumulating

+3% holders QoQ · +99 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.28% of float · ▼ -95.7% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

391 holders — near 3-yr high, broad support

Fundamentals

Excellent

Revenue growth +16%

Y/Y

EPS growth +28%

Y/Y

Free cash flow $208.6M

Valuation P/E 18.2

below peers

Buyback $200.0M

authorized

Balance sheet $709.2M

net cash

Quant / Vol

risk profile

Limited

Not enough data for a confident read.

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 2

Latest guidance · from the Earnings Call filed Dec 31, 2025

Total revenue · 2026 $615M – $645M

FIRDAPSE · 2026 $435M – $450M

AGAMREE · 2026 $140M – $150M

FYCOMPA · 2026 $40M – $45M

Prior guidance period ended · from the Earnings Call filed Sep 30, 2025

Total revenue · 2025 $565M – $585M

Total net product revenue · full year $355M – $360M

Net product revenue · full year $100M – $110M

Net product revenue · full year $105M – $115M

Guided vs delivered · last 2 settled

Total net revenues full year 2024

guided $455M – $475M

guided $455M – $475M $491.73M Beat +5.7%

2023 total revenue 2023

guided $390M – $395M

guided $390M – $395M $398.2M Beat +1.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CPRX Catalyst Pharmaceuticals, Inc. this stock	$3.85B	—	+16.4%	18.2	0.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
ARGX Argenx SE	$64.56B	+23.4%	—	—	2.1%
CSLLY Csl Ltd	$58.31B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

391

% held: 88.0%
Net QoQ: +2.9M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

366

View

Short & Settlement

Short Interest Falling

Shares short

340.3K

Days to cover: 1.0d
Change: -7.5M sh

View

Short Volume

Short vol %

42%

As of: Jul 14, 2026

Short Total

View

Fails to Deliver

FTD shares

170

Value: $5.4K
As of: Jul 15, 2026

View

Financials

Revenue (FY)

$589.0M

Net income (FY): $214.3M
EPS diluted: $1.68

View

Buybacks

Authorized

$200.0M

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 16, 2026
This year: 13

View

Proposed Sales

Value

$621.9K

Shares: 26.7K
Filed: Dec 12, 2025

View

Earnings & Events

Earnings Calls

Last call

May 12, 2026

View

Investor Relations